Zhitong Finance App News, Leadman (300289.SZ) announced that the company recently learned that the recombinant B-group meningococcal vaccine (Escherichia coli) (“recombinant group B meningococcal vaccine”) independently developed by the holding subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) has begun phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Leadman (300289.SZ) announced that the company recently learned that the recombinant B-group meningococcal vaccine (Escherichia coli) (“recombinant group B meningococcal vaccine”) independently developed by the holding subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) has begun phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control.